The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
- PMID: 26996659
- DOI: 10.1016/j.eururo.2016.02.028
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
Abstract
It has been 12 yr since the publication of the last World Health Organization (WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours. Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 WHO classification. In most cases, it represents intraductal spread of aggressive prostatic carcinoma and should be separated from high-grade prostatic intraepithelial neoplasia. New acinar adenocarcinoma variants are microcystic adenocarcinoma and pleomorphic giant cell adenocarcinoma. Modifications to the Gleason grading system are incorporated into the 2016 WHO section on grading of prostate cancer, and it is recommended that the percentage of pattern 4 should be reported for Gleason score 7. The new WHO classification further recommends the recently developed prostate cancer grade grouping with five grade groups. For bladder cancer, the 2016 WHO classification continues to recommend the 1997 International Society of Urological Pathology grading classification. Newly described or better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential, which is frequently identified in patients with a prior history of urothelial carcinoma. Invasive urothelial carcinoma with divergent differentiation refers to tumours with some percentage of "usual type" urothelial carcinoma combined with other morphologies. Pathologists should mention the percentage of divergent histologies in the pathology report.
Patient summary: Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 World Health Organization classification. Better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential.
Keywords: Bladder; Prostate; WHO classification.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Pathology and Genetics: Tumours of the Urinary System and Male Genital System: Clinical Implications of the 4th Edition of the WHO Classification and Beyond.Eur Urol. 2016 Jul;70(1):120-123. doi: 10.1016/j.eururo.2016.03.011. Epub 2016 Mar 17. Eur Urol. 2016. PMID: 26996660 No abstract available.
Similar articles
-
Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.Am J Surg Pathol. 2014 Jul;38(7):941-5. doi: 10.1097/PAS.0000000000000178. Am J Surg Pathol. 2014. PMID: 24503758
-
Histologic grading of urothelial carcinoma: a reappraisal.Hum Pathol. 2012 Dec;43(12):2097-108. doi: 10.1016/j.humpath.2012.01.008. Epub 2012 Apr 26. Hum Pathol. 2012. PMID: 22542126
-
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. Am J Surg Pathol. 2016. PMID: 26492179 Review.
-
Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016".Eur Urol Focus. 2019 May;5(3):457-466. doi: 10.1016/j.euf.2018.01.003. Epub 2018 Jan 20. Eur Urol Focus. 2019. PMID: 29366854 Review.
-
Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.Am J Surg Pathol. 2017 Apr;41(4):e1-e7. doi: 10.1097/PAS.0000000000000820. Am J Surg Pathol. 2017. PMID: 28177964
Cited by
-
Stromal Lymphoid Response Status in Micropapillary Urothelial Carcinomas Diagnosed in Bladder Transurethral Resections and its Comparison with Conventional Urothelial Carcinomas.Turk Patoloji Derg. 2021;37(1):26-31. doi: 10.5146/tjpath.2020.01497. Turk Patoloji Derg. 2021. PMID: 32692402 Free PMC article.
-
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.Front Oncol. 2021 May 20;11:671969. doi: 10.3389/fonc.2021.671969. eCollection 2021. Front Oncol. 2021. PMID: 34094973 Free PMC article.
-
Clinical evolution of bladder carcinosarcoma: A case report and literature review.Medicine (Baltimore). 2024 Aug 9;103(32):e39225. doi: 10.1097/MD.0000000000039225. Medicine (Baltimore). 2024. PMID: 39121313 Free PMC article. Review.
-
NFE2L3 as a Potential Functional Gene Regulating Immune Microenvironment in Human Kidney Cancer.Biomed Res Int. 2022 Oct 26;2022:9085186. doi: 10.1155/2022/9085186. eCollection 2022. Biomed Res Int. 2022. PMID: 36337840 Free PMC article.
-
Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma.J Immunother Cancer. 2020 Jul;8(2):e000419. doi: 10.1136/jitc-2019-000419. J Immunother Cancer. 2020. PMID: 32641319 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical